
## Annamaria Fra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4467549/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The molecular species responsible for α 1 â€antitrypsin deficiency are suppressed by a small molecule chaperone. FEBS Journal, 2021, 288, 2222-2237.	2.2	8
2	The Importance of N186 in the Alpha-1-Antitrypsin Shutter Region Is Revealed by the Novel Bologna Deficiency Variant. International Journal of Molecular Sciences, 2021, 22, 5668.	1.8	5
3	Neuroserpin: structure, function, physiology and pathology. Cellular and Molecular Life Sciences, 2021, 78, 6409-6430.	2.4	16
4	ALPHA1-ANTITRYPSIN DEFICIENCY: A 25-YEAR EXPERIENCE. Chest, 2020, 157, A177.	0.4	0
5	Intrahepatic heteropolymerization of M and Z alpha-1-antitrypsin. JCl Insight, 2020, 5, .	2.3	16
6	Characterisation of a type II functionally-deficient variant of alpha-1-antitrypsin discovered in the general population. PLoS ONE, 2019, 14, e0206955.	1.1	13
7	Intermittent C1-Inhibitor Deficiency Associated with Recessive Inheritance: Functional and Structural Insight. Scientific Reports, 2018, 8, 977.	1.6	22
8	Heteropolymerization of α-1-antitrypsin mutants in cell models mimicking heterozygosity. Human Molecular Genetics, 2018, 27, 1785-1793.	1.4	24
9	Cellular Models for the Serpinopathies. Methods in Molecular Biology, 2018, 1826, 109-121.	0.4	9
10	Real-world clinical applicability of pathogenicity predictors assessed on <i>SERPINA1</i> mutations in alpha-1-antitrypsin deficiency. Human Mutation, 2018, 39, 1203-1213.	1.1	36
11	The pathological Trento variant of alphaâ€1â€antitrypsin (E75V) shows nonclassical behaviour during polymerization. FEBS Journal, 2017, 284, 2110-2126.	2.2	23
12	Cysteines as Redox Molecular Switches and Targets of Disease. Frontiers in Molecular Neuroscience, 2017, 10, 167.	1.4	95
13	Polymers of Z α <sub>1</sub> -antitrypsin are secreted in cell models of disease. European Respiratory Journal, 2016, 47, 1005-1009.	3.1	41
14	Aberrant disulphide bonding contributes to the ER retention of alpha1-antitrypsin deficiency variants. Human Molecular Genetics, 2016, 25, 642-650.	1.4	28
15	Identification and characterisation of eight novel SERPINA1 Null mutations. Orphanet Journal of Rare Diseases, 2014, 9, 172.	1.2	60
16	The Decrease of Mineralcorticoid Receptor Drives Angiogenic Pathways in Colorectal Cancer. PLoS ONE, 2013, 8, e59410.	1.1	30
17	Three New Alpha1-Antitrypsin Deficiency Variants Help to Define a C-Terminal Region Regulating Conformational Change and Polymerization. PLoS ONE, 2012, 7, e38405.	1.1	43
18	Different molecular behavior of CD40 mutants causing hyper-IgM syndrome. Blood, 2010, 116, 5867-5874.	0.6	29

Annamaria Fra

#	Article	IF	CITATIONS
19	CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells. Molecular Immunology, 2010, 47, 1356-1365.	1.0	56
20	Molecular characterization of the new defective P <sub>brescia</sub> alpha1-antitrypsin allele. Human Mutation, 2009, 30, E771-E781.	1.1	27
21	Phenotypic behavior of C2C12 myoblasts upon expression of the dystrophyâ€related caveolinâ€3 P104L and TFT mutants. FEBS Letters, 2007, 581, 5099-5104.	1.3	13
22	Mechanisms of interleukin-6 protection against ischemia–reperfusion injury in rat liver. Cytokine, 2006, 34, 131-142.	1.4	37
23	Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO Journal, 2006, 25, 1104-1113.	3.5	139
24	Generation and characterization of a mouse lymphatic endothelial cell line. Cell and Tissue Research, 2006, 325, 91-100.	1.5	56
25	Differential Recognition and Scavenging of Native and Truncated Macrophage-Derived Chemokine (Macrophage-Derived Chemokine/CC Chemokine Ligand 22) by the D6 Decoy Receptor. Journal of Immunology, 2004, 172, 4972-4976.	0.4	132
26	Cutting Edge: Scavenging of Inflammatory CC Chemokines by the Promiscuous Putatively Silent Chemokine Receptor D6. Journal of Immunology, 2003, 170, 2279-2282.	0.4	181
27	Degradation of unassembled soluble Ig subunits by cytosolic proteasomes: evidence that retrotranslocation and degradation are coupled events. FASEB Journal, 2000, 14, 769-778.	0.2	96
28	Genomic organization and transcriptional analysis of the human genes coding for caveolin-1 and caveolin-2. Gene, 2000, 243, 75-83.	1.0	29
29	Human Caveolin-1 and Caveolin-2 Are Closely Linked Genes Colocalized with WI-5336 in a Region of 7q31 Frequently Deleted in Tumors. Genomics, 1999, 56, 355-356.	1.3	26
30	Caveolin-1 and -2 in the Exocytic Pathway of MDCK Cells. Journal of Cell Biology, 1998, 140, 795-806.	2.3	283
31	Exposed Thiols Confer Localization in the Endoplasmic Reticulum by Retention Rather than Retrieval. Journal of Biological Chemistry, 1996, 271, 26138-26142.	1.6	40
32	De novo formation of caveolae in lymphocytes by expression of VIP21-caveolin Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 8655-8659.	3.3	555
33	A photo-reactive derivative of ganglioside GM1 specifically cross-links VIP21-caveolin on the cell surface. FEBS Letters, 1995, 375, 11-14.	1.3	169
34	The efficiency of cysteine-mediated intracellular retention determines the differential fate of secretory IgA and IgM in B and plasma cells. European Journal of Immunology, 1994, 24, 2477-2482.	1.6	42
35	Quality control of ER synthesized proteins: an exposed thiol group as a three-way switch mediating assembly, retention and degradation EMBO Journal, 1993, 12, 4755-4761.	3.5	124
36	The Endoplasmic Reticulum as a Site of Protein Degradation. Sub-Cellular Biochemistry, 1993, 21, 143-168.	1.0	36

#	Article	IF	CITATIONS
37	Developmental regulation of IgM secretion: The role of the carboxy-terminal cysteine. Cell, 1990, 60, 781-790.	13.5	248